secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2021-09-20T23:59:59+00:00
Accession:  0001171843-21-006545
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst appoints former FDA deputy center director Dr. Amy McKee to board of directors
--------------------------------------------------------------------------------

- Board expanded from 10 to 11 members; Dr. McKee elected effective September 20, 2021.
- Dr. McKee served as Deputy Center Director for FDA's Oncology Center of Excellence and is now VP at Parexel.
- Dr. McKee to serve on Science Committee; receives initial grant of 53,333 stock options plus annual grants of 40,000 options.
- Appointment brings regulatory expertise as BioCryst advances BCX9930 into pivotal trials for PNH and other complement diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184321006545/0001171843-21-006545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184321006545/f8k_092021.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-006545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer